COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Cambridge Cardiovascular Seminar Series > Genetic and epigenetic alterations in patients with congenital heart disease
Genetic and epigenetic alterations in patients with congenital heart diseaseAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Katja Kivinen. Please register with Katja Kivinen to attend this seminar An overview of regulatory circuits establishing the cardiac transcriptome will be shown. A particular focus is the interaction between different molecular levels, involving epigenetic, transcriptional and post-transcriptional mechanisms. Beside the study of mouse models, we apply high-throughput technology to gain insights into congenital heart disease with a particular interest on Tetralogy of Fallot (ToF). More than ten years ago we provided the first genome-wide expression profiles of normal and diseased human hearts. More recently, we showed that ToF is an oligogenetic disorder and most interestingly mutated genes are key factor of SHF differentiation, and we predict that impaired differentiation and proliferation capacity of SHF progenitors is one main impact on the dys-developed. In addition, we just conducted a genome-wide study of DNA methylation alteration. We linked DNA methylation with genome-wide expression data and found a significant overlap for hypermethylated promoters and down-regulated genes, and vice versa. Among the differentially methylated genes with distinct expression changes are the sarcomeric component TNNI1 , the co-receptor TDGF1 , the endothelin converting enzyme ECE2 , and the cytochrome C oxidase assembly protein SCO2 . Moreover, we found examples of methylation changes co-localized with novel, differential splicing events among sarcomeric genes. Finally, we demonstrate the interaction of differentially methylated and expressed genes in TOF with mutated CHD genes in a molecular network. In order to perform functional follow up studies, we currently apply human iPSCs technology and their differentiation to cardiomyocytes This talk is part of the Cambridge Cardiovascular Seminar Series series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsType the title of a new list here IfM Seminars Epigenetics and Stem Cells 2012 TQS Journal Clubs Cambridge PhD ClinicOther talksSt Catharine’s Political Economy Seminar - ‘Technological Unemployment: Myth or Reality’ by Robert Skidelsky Large Scale Ubiquitous Data Sources for Crime Prediction Sine-Gordon on a Wormhole C++11/14 - the new C++ Psychological predictors of risky online behaviour: The cases of online piracy and privacy Active Machine Learning: From Theory to Practice |